Cellectar Biosciences, Inc. (CLRB)
CLRB Stock Price Chart
Explore Cellectar Biosciences, Inc. interactive price chart. Choose custom timeframes to analyze CLRB price movements and trends.
CLRB Company Profile
Discover essential business fundamentals and corporate details for Cellectar Biosciences, Inc. (CLRB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
10 Nov 2005
Employees
11.00
Website
https://www.cellectar.comCEO
James V. Caruso
Description
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
CLRB Financial Timeline
Browse a chronological timeline of Cellectar Biosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.55, while revenue estimate is $12.00m.
Earnings released on 14 May 2026
EPS came in at -$1.33 surpassing the estimated -$1.89 by +29.44%.
Earnings released on 4 Mar 2026
EPS came in at -$0.53 surpassing the estimated -$1.19 by +55.46%.
Earnings released on 13 Nov 2025
EPS came in at -$1.41 surpassing the estimated -$1.91 by +26.18%.
Earnings released on 14 Aug 2025
EPS came in at -$3.39 surpassing the estimated -$3.60 by +5.83%.
Stock split effective on 23 Jun 2025
Shares were split 1 : 30 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 May 2025
EPS came in at -$3.90 surpassing the estimated -$5.11 by +23.68%.
Earnings released on 13 Mar 2025
EPS came in at -$0.01 surpassing the estimated -$0.38 by +97.37%.
Earnings released on 18 Nov 2024
EPS came in at -$16.52 falling short of the estimated -$0.35 by -4.59k%.
Earnings released on 13 Aug 2024
EPS came in at -$0.73 falling short of the estimated -$0.23 by -217.39%.
Earnings released on 14 May 2024
EPS came in at -$0.40 surpassing the estimated -$0.50 by +20.00%.
Earnings released on 27 Mar 2024
EPS came in at -$0.66 falling short of the estimated -$0.59 by -11.86%, while revenue for the quarter reached $330.37k .
Earnings released on 13 Nov 2023
EPS came in at -$24.62 falling short of the estimated -$13.21 by -86.37%.
Earnings released on 14 Aug 2023
EPS came in at -$0.73 falling short of the estimated -$0.69 by -5.80%.
Earnings released on 4 May 2023
EPS came in at -$0.76 falling short of the estimated -$0.75 by -1.33%.
Earnings released on 9 Mar 2023
EPS came in at -$0.55 surpassing the estimated -$0.83 by +33.73%.
Earnings released on 3 Nov 2022
EPS came in at -$1.28 falling short of the estimated -$1.21 by -5.79%.
Earnings released on 5 Aug 2022
EPS came in at -$1.22 falling short of the estimated -$1.08 by -12.96%.
Stock split effective on 21 Jul 2022
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 May 2022
EPS came in at -$1.00 surpassing the estimated -$1.10 by +9.09%.
Earnings released on 21 Mar 2022
EPS came in at -$1.00 matching the estimated -$1.00.
Earnings released on 8 Nov 2021
EPS came in at -$1.00 surpassing the estimated -$1.10 by +9.09%.
Earnings released on 9 Aug 2021
EPS came in at -$1.10 matching the estimated -$1.10.
CLRB Stock Performance
Access detailed CLRB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
